SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 29, 2019
Innovate Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
8480 Honeycutt Road, Suite 120, Raleigh, NC 27615
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, include area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
On April 29, 2019, Innovate Biopharmaceuticals, Inc. (the “Company”) issued a press release with an update on certain operational matters, including data with respect to preclinical studies for larazotide in nonalcoholic steatohepatitis (NASH). A copy of such release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Innovate Biopharmaceuticals, Inc.
Date: April 29, 2019
/s/ Jay P. Madan
Jay P. Madan
President and Chief Business Officer
Innovate Biopharmaceuticals Shows Larazotide is the First Drug, with its Novel Mechanism of Action of Re-normalizing the Intestinal Barrier, to Demonstrate Improvements in validated NASH Biomarkers and Endpoints in synergy with obeticholic acid, an FXR agonist, and Reports key first quarter 2019 financial results and operational highlights
Continued execution toward start of the first phase 3 celiac disease clinical trial in the current quarter with key sites for trial launch selected and active recruitment efforts underway
NASH Data Presentation at Analyst Meeting at Digestive Disease Week (DDW) conference on May 20, 2019 in San Diego
RALEIGH, N.C., April 29, 2019, Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced today that larazotide acetate, a new class of medicine based on gut-restricted peptides which re-normalize the intestinal epithelial barrier and gut-liver axis, is the first drug with this novel mechanism to shown improvements in validated NASH biomarkers and endpoints. Key topline findings from a biopsy-proven translational mouse model of NASH (the AMLN-diet Gubra NASH mouse model) will be presented at an Analyst Meeting at the Digestive Disease Week (DDW) conference on May 20, 2019 in San Diego as well submitted to The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD) in fall, 2019.
Active patient recruitment efforts underway
Selected more than 100 clinical research sites to participate in our registration trial: CeD-LA-3001 Study: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet.
Immuno-oncology: started academic collaboration with Institut Gustave Roussy to study regulation of intestinal permeability and the gut microbiota using larazotide in immuno-oncology checkpoint inhibitor failure preclinical models
Start of patient screening and randomization for the first phase 3 celiac disease trial
NASH data presentation at Analyst Meeting at Digestive Disease Week (DDW) conference on May 20, 2019 in San Diego
Further updates on NASH pathway for clinical development
Continuation of pre-clinical studies for alcoholic steatohepatitis (ASH)
Initiation of additional scientific and clinical collaborations
NASH Pre-clinical Data Highlights
In a 12 week preclinical study of larazotide acetate combined with obeticholic acid (OCA), data demonstrated statistically significant reductions in plasma total cholesterol (p<0.001), absolute (p<0.05) and relative liver weights (p<0.01), relative (p<0.001) and total liver cholesterol (p<0.001), and relative (p<0.01) and absolute liver triglycerides (p<0.001), when compared to vehicle control animals that did not receive any larazotide or OCA. The non-alcoholic fatty liver disease activity score (NAS score), the clinical measure of NASH activity, improved in the majority of animals treated with the combination of larazotide/OCA when compared to vehicle (p<0.001).
Histological steatosis scores trended positively, and lobular inflammation was statistically significantly improved (p<0.01) in the larazotide/OCA group when compared to vehicle control animals.
Dr. Stephen Harrison, Medical Director of Pinnacle Clinical Research in San Antonio, Texas, an expert in clinical trials for NASH said, “These preclinical data, demonstrating a synergistic effect of larazotide, which targets intestinal permeability, when combined with obeticholic acid, a well characterized farnesoid X receptor (FXR) agonist’. Dr Harrison added, “the data mandates a clinical study to understand this novel mechanism’s effect in patients. There is a high unmet need for NASH and agents which may improve existing modalities via novel mechanisms would greatly benefit patients.”
Sandeep Laumas, M.D., CEO of Innovate, said, “The first quarter of 2019 was focused on continued preparation for the first celiac disease phase 3 clinical trial. Larazotide’s positive effect in a pre-clinical model has, for the first time shown, a novel mechanism for treatment of NASH in combination with other drugs. We are very excited with this data along with previous preclinical studies (AASLD 2018 abstracts) could seek to move to a proof-of concept clinical trial after receipt of additional financing. The unique mechanism of larazotide has consistently proven itself in a series of models for multiple diseases. We are also awaiting data from the immuno-oncology microbiome study which is studying larazotide’s effect on converting checkpoint inhibitor / PD-1 non-responders to responders via modulation of gut permeability and the microbiome.”
2019 First Quarter Financial Results
As previously disclosed, as of March 31, 2019, Innovate had estimated unaudited cash and cash equivalents of $11.5 million, compared to $5.7 million at December 31, 2018. This is a preliminary unaudited estimate of the cash and cash equivalents of the Company as of March 31, 2019.
As previously announced, Innovate plans to host a conference call at 8:00 am ET today, April 29, 2019, to discuss certain of its financial results for the first quarter ended March 31, 2019, and to provide operational updates. Please visit the Investor section of Innovate’s website for further details on accessing the webcast.
A live and archived audio webcast of the conference call will be available on the Events and Presentations page of Innovate’s corporate website at www.innovatebiopharma.com.
Nonalcoholic steatohepatitis (NASH) is a severe disease of the liver caused by inflammation and a buildup of fat in the organ. In the United States, NASH affects up to approximately 2-5% of the population. An additional 10-30% of Americans have fat in their livers, but no inflammation or liver damage, a condition called NAFLD or “fatty liver.” The underlying cause of NASH is unclear, but it most often occurs in persons who are middle-aged and overweight or obese. It has been shown that chronic liver diseases, including NAFLD/NASH, may cause perturbations in the epithelial lining of the gut, and disrupt barrier integrity, causing a normal intestine to become more permeable. This “leaky gut” could cause passage of unwanted toxins and antigenic components to “cross-talk” to the liver via the blood circulation causing inflammation and damage to hepatocytes. This gut-liver axis is an emerging area of research in chronic liver diseases, such as NAFLD/NASH.
About Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT)
Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in nonalcoholic steatohepatitis (NASH). In several diseases, including celiac disease, NASH, Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD), the intestinal barrier is dysfunctional with increased permeability.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, capital raising, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials, including, without limitation, raising additional funds for our Phase 3 registration trial for INN-202, and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. These risks and uncertainties include, but may not be limited to, those described in our Annual Report on Form 10-K filed with the SEC on March 18, 2019, and in any subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
SOURCE: Innovate Biopharmaceuticals, Inc.
Innovate Biopharmaceuticals, Inc.
Jennifer K. Zimmons, Ph.D.